Gemini Therapeutics Inc Stock
Gemini Therapeutics Inc Stock price
Key metrics
| Market capitalization | $1.91b |
| Enterprise Value | $1.42b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 4.08 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-124.88m |
| Free Cash Flow (TTM) Free Cash Flow | $-84.21m |
| Cash position | $487.36m |
Is Gemini Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Gemini Therapeutics Inc Stock Analysis
Analyst Opinions
11 Analysts have issued a Gemini Therapeutics Inc forecast:
Analyst Opinions
11 Analysts have issued a Gemini Therapeutics Inc forecast:
Financial data from Gemini Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.17 -0.17 |
67%
67%
|
|
| EBITDA | -125 -125 |
51%
51%
|
EBIT (Operating Income) EBIT | -125 -125 |
50%
50%
|
| Net Profit | -103 -103 |
40%
40%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Gemini Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | John Quisel |
| Employees | 74 |
| Founded | 2017 |
| Website | www.discmedicine.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
